Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.
about
Biological features and biomarkers in hepatocellular carcinomaDevelopment of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival.Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma.Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma.Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma.Inhibition of microRNA-126 promotes the expression of Spred1 to inhibit angiogenesis in hepatocellular carcinoma after transcatheter arterial chemoembolization: in vivo studySafety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.Predictive factors in patients with hepatocellular carcinoma receiving sorafenib therapy using time-dependent receiver operating characteristic analysis.On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib.Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib.Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.Adoption of Sorafenib for the Treatment of Advanced-Stage Hepatocellular Carcinoma in Oncology Practices in the United States.Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis.Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept.Effects of dexmedetomidine on perioperative stress response, inflammation and immune function in patients with different degrees of liver cirrhosis
P2860
Q26799462-10FC8F4D-2B51-47BB-8E2E-08E69732B584Q30240748-EC0408A0-0D2D-45B3-856C-82D7191875C3Q33591514-9D97001E-75EC-410A-9C23-2A4A71ECC918Q35793100-88031FCF-7DDF-4DDD-A02A-D01754F8AA9CQ36106903-6A44D25F-0995-42FC-A38F-43704C2EDEB9Q37122785-48B36CE4-340F-4933-A41D-9400948AC30EQ37284654-06643641-E0A2-4818-AEAD-D2EFE37CBD28Q37675947-398EB609-AAE6-4D5A-8E67-B00112BDCCCEQ38933901-D1C70F74-6D08-473C-8F86-80C4941F6AC1Q39473582-A28F18E0-B472-4C94-98A0-4E7FC869B8B8Q40106296-316DEB98-652D-45A9-977C-28E923C15C4BQ40436895-03376C4A-8DC7-49F3-9EE5-29FF73F9E992Q41962614-D4A56231-BA3C-41A9-B937-FD030AE2FCE4Q47194525-54B87093-A2BA-4918-B7D1-26391F91CCF4Q48166586-B785B3EC-FFA7-4337-8FD6-ADA0B263501EQ49884630-481EBD3E-3EE3-4DE1-B886-C60DC4E7B29CQ50169188-3EC3C062-673E-4561-AEAA-AE87838C82A8Q55646454-A3F8ED25-7C2C-467D-80D0-B073801647A5Q57787078-E0551AF0-55E6-4B15-8DC6-9F93B4BD97B9
P2860
Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Sorafenib treatment in Child-P ...... ficacy and prognostic factors.
@en
Sorafenib treatment in Child-P ...... ficacy and prognostic factors.
@nl
type
label
Sorafenib treatment in Child-P ...... ficacy and prognostic factors.
@en
Sorafenib treatment in Child-P ...... ficacy and prognostic factors.
@nl
prefLabel
Sorafenib treatment in Child-P ...... ficacy and prognostic factors.
@en
Sorafenib treatment in Child-P ...... ficacy and prognostic factors.
@nl
P2093
P2860
P1476
Sorafenib treatment in Child-P ...... ficacy and prognostic factors.
@en
P2093
Akinobu Tawada
Eiichiro Suzuki
Fumihiko Kanai
Naoya Kanogawa
Osamu Yokosuka
Sadahisa Ogasawara
Tenyu Motoyama
Tetsuhiro Chiba
Tomoko Saito
Yoshihiko Ooka
P2860
P2888
P304
P356
10.1007/S10637-015-0237-3
P577
2015-04-12T00:00:00Z